AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8631089 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms genetic engineering vaccines against hepatitis B; administered at same intervals as group 1.
Number of subjects: 142
Study 8631089 — intervention group
Group type: COMPARATOR
Intervention: 10 micrograms genetic engineering vaccines against hepatitis B plus HBIG (1ml, 200 U/ml); administered at same intervals as group 1.
Number of subjects: 142
Study 2178852 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 65
Study 2178852 — intervention group
Group type: COMPARATOR
Intervention: Control group (behavioral smoking-cessation program without nicotine patch)
Number of subjects: 65
Study 6104934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 118
Study 6104934 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 118
Study 30663425 — intervention group
Group type: EXPERIMENTAL
Intervention: CRet trial
Number of subjects: 16
Study 30663425 — intervention group
Group type: COMPARATOR
Intervention: Sham trial
Number of subjects: 16
Study 30372779 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA lanolin
Number of subjects: 180
Study 30372779 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 180
Study 27022913 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Low Fat (SLF, 55% carbohydrate; 20% protein; 25% fat, n = 36)
Number of subjects: 87
Study 27022913 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Modified Carbohydrate (SMC, 35% carbohydrate; 30% protein; 35% fat, n = 37)
Number of subjects: 87
Study 27022913 — intervention group
Group type: COMPARATOR
Intervention: Wait listed control group (n = 14)
Number of subjects: 87
Study 27022913 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Low Fat (SLF)
Number of subjects: 87
Study 27022913 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Modified Carbohydrate (SMC)
Number of subjects: 87
Study 24521874 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg/day over four weeks)
Number of subjects: 15
Study 24521874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22344231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 22344231 — intervention group
Group type: COMPARATOR
Intervention: IFN-α
Number of subjects: 0
Study 19450036 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk information for diabetes, heart disease, colon cancer, or lung cancer with lifetime risk varying by 10% increments (20% to 100%).
Number of subjects: 752
Study 19450036 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk information for diabetes, heart disease, colon cancer, or lung cancer.
Number of subjects: 752
Study 17454718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures containing smoking related‐content
Number of subjects: 23
Study 17454718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures devoid of smoking content
Number of subjects: 23
Study 17454718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation cross
Number of subjects: 23
Study 15174545 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 108
Study 15174545 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle reconstruction
Number of subjects: 108
Study 10601673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine (75, 150, or 300 micrograms)
Number of subjects: 24
Study 10601673 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (150, 300, or 600 micrograms)
Number of subjects: 24
Study 10601673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine
Number of subjects: 24
Study 10601673 — intervention group
Group type: COMPARATOR
Intervention: Epidural clonidine
Number of subjects: 24
Study 10601673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal and epidural clonidine
Number of subjects: 24
Study 9351353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 5
Study 8382534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 50 mg
Number of subjects: 8
Study 8382534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 100 mg
Number of subjects: 8
Study 8382534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg
Number of subjects: 8
Study 8382534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (all doses)
Number of subjects: 8
Study 3530224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (cephalosporin) for 5 days at the operation
Number of subjects: 26
Study 3530224 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 26
Study 31634512 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 incentive
Number of subjects: 3723
Study 31634512 — intervention group
Group type: EXPERIMENTAL
Intervention: $20 incentive
Number of subjects: 3723
Study 31634512 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive call
Number of subjects: 3723
Study 31634512 — intervention group
Group type: COMPARATOR
Intervention: $10 incentive, no call
Number of subjects: 3723
Study 31634512 — intervention group
Group type: COMPARATOR
Intervention: No incentive, no call
Number of subjects: 3723
Study 28993389 — intervention group
Group type: EXPERIMENTAL
Intervention: ITEC-CHF (Innovative Telemonitoring Enhanced Care Programme)
Number of subjects: 300
Study 28993389 — intervention group
Group type: COMPARATOR
Intervention: Usual care CHF
Number of subjects: 300
Study 26233481 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 μg
Number of subjects: 3394
Study 23980081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 50 mg per day orally for 2 years
Number of subjects: 3023
Study 23980081 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3023
Study 21527567 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 29
Study 21527567 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 29
Study 18815937 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical home blood pressure monitoring (T)
Number of subjects: 223
Study 18815937 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring of office blood pressure (C)
Number of subjects: 223
Study 16430377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 0.625 mg/kg/dose
Number of subjects: 30
Study 16430377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 1.25 mg/kg/dose
Number of subjects: 30
Study 16430377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 2.5 mg/kg/dose
Number of subjects: 30
Study 16430377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12971850 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA at 0.9 mg/kg
Number of subjects: 0
Study 12971850 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA at 0.7 mg/kg
Number of subjects: 0
Study 12971850 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thrombolytic therapy)
Number of subjects: 0
Study 12971850 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic groups vs Control group
Number of subjects: 0
Study 10671904 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine 20 mg + 0.5 g kg‐1 alcohol
Number of subjects: 20
Study 10671904 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine 20 mg + placebo alcohol
Number of subjects: 20
Study 10671904 — intervention group
Group type: COMPARATOR
Intervention: placebo capsules + 0.5 g kg‐1 alcohol
Number of subjects: 20
Study 10671904 — intervention group
Group type: COMPARATOR
Intervention: placebo capsules + placebo alcohol
Number of subjects: 20
Study 9347598 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (2400 mg over 48 h)
Number of subjects: 25
Study 9347598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8407006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nifedipine (0.2 mg)
Number of subjects: 67
Study 8407006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 3536231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone/prednisone for four months
Number of subjects: 34
Study 3536231 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid therapy (Control)
Number of subjects: 34
Study 3536231 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 34
Study 30953107 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg s.c.
Number of subjects: 421
Study 30953107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 29237033 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Number of subjects: 100
Study 29237033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29118231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored strategies to engage referring sites and patients
Number of subjects: 223
Study 25288048 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive physiotherapy
Number of subjects: 111
Study 25288048 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (neck massage)
Number of subjects: 111
Study 25288048 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 111
Study 23664859 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking with riboflavin photosensitization and ultraviolet irradiation
Number of subjects: 16
Study 20362849 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue 0.1% staining
Number of subjects: 30
Study 20362849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trypan blue)
Number of subjects: 30
Study 18238840 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressomyograph (CMG)
Number of subjects: 16
Study 18238840 — intervention group
Group type: COMPARATOR
Intervention: Mechanomyograph (MMG)
Number of subjects: 16
Study 16735449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day)
Number of subjects: 16
Study 16735449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16735449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone with lipid infusion
Number of subjects: 16
Study 12749425 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified long protocol (standard agonist dose until pituitary down-regulation, then halved during stimulation)
Number of subjects: 60
Study 12749425 — intervention group
Group type: COMPARATOR
Intervention: Modified flare protocol (high dose of GnRH agonist for first 4 days, then standard agonist dose)
Number of subjects: 60
Study 11100893 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 153
Study 8140941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic estrogen‐progestagen replacement treatment plus nandrolone decanoate (ND)
Number of subjects: 33
Study 8140941 — intervention group
Group type: COMPARATOR
Intervention: Cyclic estrogen‐progestagen replacement treatment (control group)
Number of subjects: 33
Study 2457657 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide + cisplatin (EP)
Number of subjects: 164
Study 2457657 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin (VAB-6)
Number of subjects: 164
Study 29537903 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative gum chewing
Number of subjects: 78
Study 29537903 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopenia
Number of subjects: 78
Study 29537903 — intervention group
Group type: COMPARATOR
Intervention: Control group (without myopenia)
Number of subjects: 78
Study 27940186 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal navigation by a lay health worker
Number of subjects: 0
Study 27940186 — intervention group
Group type: COMPARATOR
Intervention: Control care
Number of subjects: 0
Study 29264989 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-term multimodal psychotherapy
Number of subjects: 200
Study 29264989 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 200
Study 24094907 — intervention group
Group type: EXPERIMENTAL
Intervention: EMOTIV Headset
Number of subjects: 10
Study 24094907 — intervention group
Group type: COMPARATOR
Intervention: Six disc electrodes
Number of subjects: 10
Study 24094907 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of electrode types (disc, needle, large squared)
Number of subjects: 10
Study 21418411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 60
Study 21418411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl followed by 17% EDTA
Number of subjects: 60
Study 21418411 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CX
Number of subjects: 60
Study 21418411 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CX followed by 17% EDTA
Number of subjects: 60
Study 21418411 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 60
Study 21418411 — intervention group
Group type: COMPARATOR
Intervention: Control (without irrigant solution)
Number of subjects: 60
Study 19234845 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 19234845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 19234845 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 30
Study 17620776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection at 4 weeks after surgery
Number of subjects: 120
Study 17620776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection at 8 weeks after surgery
Number of subjects: 120
Study 17620776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection at 12 weeks after surgery
Number of subjects: 120
Study 17620776 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection at 4 weeks after surgery (Control)
Number of subjects: 120
Study 14982985 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg (2 mL)
Number of subjects: 12
Study 14982985 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 12
Study 11167437 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intrathecal diamorphine
Number of subjects: 40
Study 11167437 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg intrathecal diamorphine
Number of subjects: 40
Study 9566833 — intervention group
Group type: EXPERIMENTAL
Intervention: Total paracentesis
Number of subjects: 46
Study 7796796 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate, titrated to a maximum daily dose of 3600 mg over 2 days
Number of subjects: 52
Study 7796796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2351162 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-R pacing
Number of subjects: 40
Study 2351162 — intervention group
Group type: COMPARATOR
Intervention: AAI pacing
Number of subjects: 40
Study 520397 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 7.5, 15 and 30 mg i.v.
Number of subjects: 8
Study 520397 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 30, 60 and 120 mg i.v.
Number of subjects: 8
Study 520397 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 520397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Propranolol and Labetalol)
Number of subjects: 8
Study 30694752 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine in one‐per‐mil tumescent solution (1:1,000,000 epinephrine and 0.2% lidocaine)
Number of subjects: 12
Study 30694752 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 12
Study 28143679 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (12 weeks, twice per week)
Number of subjects: 50
Study 28143679 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group activities (comparison condition)
Number of subjects: 50
Study 28143679 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 50
Study 25875131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of buried interrupted subcuticular sutures and adhesive strips
Number of subjects: 48
Study 25875131 — intervention group
Group type: COMPARATOR
Intervention: Buried interrupted subcuticular sutures only
Number of subjects: 48
Study 25875131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 48
Study 22898437 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 165
Study 22898437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 22898437 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication and coping skills training
Number of subjects: 165
Study 22898437 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 165
Study 21529314 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic CPAP (APAP)
Number of subjects: 17
Study 21529314 — intervention group
Group type: COMPARATOR
Intervention: Fixed CPAP
Number of subjects: 17
Study 21529314 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 17
Study 18480967 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate multilayer compression bandaging
Number of subjects: 69
Study 18480967 — intervention group
Group type: COMPARATOR
Intervention: No bandaging (control)
Number of subjects: 69
Study 17121193 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment before dental procedures
Number of subjects: 100
Study 17121193 — intervention group
Group type: COMPARATOR
Intervention: No psychological treatment before dental procedures
Number of subjects: 100
Study 15597216 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 9000
Study 15597216 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 9000
Study 11383811 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical sealant applied to sites at risk for air leak after standard methods of lung closure
Number of subjects: 172
Study 11383811 — intervention group
Group type: COMPARATOR
Intervention: Standard lung closure only
Number of subjects: 172
Study 9223200 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control group)
Number of subjects: 80
Study 9223200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 15 mg every 6 hours
Number of subjects: 80
Study 9223200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg every 6 hours
Number of subjects: 80
Study 9223200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac added to PCA morphine on a milligram per milligram basis
Number of subjects: 80
Study 7936530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine (80 mL of 0.5% lidocaine with 1/320,000 epinephrine and 10 mL of 2% lidocaine with 1/80,000 epinephrine)
Number of subjects: 50
Study 7936530 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 50
Study 3396547 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia without suxamethonium
Number of subjects: 34
Study 3396547 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium administration
Number of subjects: 34
Study 3396547 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-application of the tourniquet after short reperfusion
Number of subjects: 34
Study 3396547 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic tourniquet application
Number of subjects: 34
Study 30009652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA)
Number of subjects: 30
Study 30009652 — intervention group
Group type: COMPARATOR
Intervention: Sham intradermal acupuncture (sham IA)
Number of subjects: 30
Study 27184542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure Platelet-Rich Plasma (PRP) injection
Number of subjects: 120
Study 27184542 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine injection (control)
Number of subjects: 120
Study 25512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Supersaturated oxygen (SSO2) infusion via left main coronary artery (LMCA) for 60 minutes after primary percutaneous coronary intervention (PCI)
Number of subjects: 20
Study 22898575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii™-based motor cognitive training (10 Wii Fit™ games)
Number of subjects: 32
Study 22898575 — intervention group
Group type: COMPARATOR
Intervention: Balance exercise therapy (14 training sessions of stretching, strengthening, and balance training)
Number of subjects: 32
Study 20821333 — intervention group
Group type: EXPERIMENTAL
Intervention: PrefCheck consultation guide
Number of subjects: 320
Study 20821333 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 320
Study 17890244 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus and low-dose cyclosporine with early steroid avoidance (group A)
Number of subjects: 133
Study 17890244 — intervention group
Group type: COMPARATOR
Intervention: Low-dose steroid treatment (group B)
Number of subjects: 133
Study 15938589 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride plus metformin (2 mg/day + 1500 mg/day)
Number of subjects: 99
Study 15938589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus metformin (4 mg/day + 1500 mg/day)
Number of subjects: 99
Study 12823090 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg/day, titrated to max 10 mg/day)
Number of subjects: 39
Study 12823090 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (0.5 mg/day, titrated to max 2.0 mg/day)
Number of subjects: 39
Study 10863887 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg per day)
Number of subjects: 61
Study 10863887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9001899 — intervention group
Group type: EXPERIMENTAL
Intervention: M.w vaccine (1 x 10(9) bacilli)
Number of subjects: 795
Study 9001899 — intervention group
Group type: EXPERIMENTAL
Intervention: M.w vaccine (5 x 10(9) bacilli)
Number of subjects: 795
Study 9001899 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 795